Immitra Bio GmbH focuses on developing innovative biopharmaceuticals that leverage advanced technologies in the field of biotechnology. The company specializes in harnessing the power of monoclonal antibodies and other biologics to create targeted therapies for various diseases. Their pipeline includes products designed to address unmet medical needs, utilizing cutting-edge research and development processes to ensure efficacy and safety in their therapeutic offerings.

In addition to monoclonal antibodies, Immitra Bio GmbH employs sophisticated techniques such as protein engineering and high-throughput screening to optimize their drug candidates. The company emphasizes a science-driven approach, integrating insights from molecular biology and immunology to enhance the specificity and potency of their treatments. This commitment to innovation positions Immitra Bio as a forward-thinking player in the biopharmaceutical industry, dedicated to improving patient outcomes through advanced therapeutic solutions.

Switzerland

At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

Immitra Bio GmbH

Company Details